Analyst Ratings For Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
Today, Cantor Fitzgerald initiated coverage on Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) with a Buy with a price target of $53.00.
There are 9 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) is Buy with a consensus target price of $51.1111 per share, a potential 43.29% upside.
Some recent analyst ratings include
- 9/6/2018-Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has coverage initiated with a Buy rating and $53.00 price target
- 8/29/2018-Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has coverage initiated with a Outperform ➝ Outperform rating and $47.00 price target
- 7/5/2018-Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has coverage initiated with a Buy rating
- 6/19/2018-Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) gets downgraded to Neutral by B. Riley with a price target of $43.00
Recent Insider Trading Activity For Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has insider ownership of 20.61% and institutional ownership of 53.49%.
- On 10/2/2017 New Leaf Venture Management Ii, Major Shareholder, bought 375,000 with an average share price of $17.00 per share and the total transaction amounting to $6,375,000.00.
About Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Recent Trading Activity for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
Shares of Deciphera Pharmaceuticals Inc closed the previous trading session at 35.67 −0.54 1.49% with shares trading hands.
